Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)‘s stock had its “buy” rating reiterated by equities research analysts at Goldman Sachs Group Inc. in a report released on Thursday. They presently have a $158.00 target price on the biopharmaceutical company’s stock. Goldman Sachs Group Inc.’s price objective suggests a potential upside of 39.06% from the company’s previous close.

ALXN has been the subject of a number of other reports. Wedbush boosted their target price on shares of Alexion Pharmaceuticals from $132.00 to $135.00 and gave the company a “neutral” rating in a report on Friday, October 28th. Zacks Investment Research downgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 2nd. Leerink Swann boosted their target price on shares of Alexion Pharmaceuticals from $210.00 to $211.00 and gave the company an “outperform” rating in a report on Monday, September 26th. Piper Jaffray Cos. set a $176.00 target price on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 6th. Finally, Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a report on Thursday, September 22nd. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $173.36.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 113.62 on Thursday. The firm has a market capitalization of $25.47 billion, a price-to-earnings ratio of 69.28 and a beta of 1.45. Alexion Pharmaceuticals has a one year low of $110.56 and a one year high of $193.45. The stock has a 50 day moving average of $123.79 and a 200-day moving average of $130.71.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.19. The business earned $799 million during the quarter, compared to the consensus estimate of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The company’s quarterly revenue was up 19.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.16 earnings per share. On average, equities analysts anticipate that Alexion Pharmaceuticals will post $4.64 earnings per share for the current fiscal year.

In other news, Director Alvin S. Parven sold 15,000 shares of the company’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $136.53, for a total transaction of $2,047,950.00. Following the completion of the transaction, the director now owns 6,373 shares in the company, valued at $870,105.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Leonard Bell sold 37,317 shares of the company’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $140.38, for a total transaction of $5,238,560.46. Following the transaction, the director now owns 440,936 shares of the company’s stock, valued at approximately $61,898,595.68. The disclosure for this sale can be found here. Company insiders own 4.41% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Global X Management Co. LLC raised its position in Alexion Pharmaceuticals by 1,416.4% in the third quarter. Global X Management Co. LLC now owns 925 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 864 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Alexion Pharmaceuticals during the first quarter valued at approximately $114,000. Cornerstone Advisors Inc. raised its position in Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 310 shares in the last quarter. NEXT Financial Group Inc raised its position in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 440 shares in the last quarter. Finally, Acrospire Investment Management LLC raised its position in Alexion Pharmaceuticals by 50.0% in the third quarter. Acrospire Investment Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 400 shares in the last quarter. Institutional investors and hedge funds own 97.33% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.